US faces "inflation problem", Fed's Hammack says - WSJ
- The US is still dealing with an "inflation problem", Cleveland Federal Reserve Bank President Beth Hammack told the Wall Street Journal in an interview published on...
- The US is still dealing with an "inflation problem", Cleveland Federal Reserve Bank President Beth Hammack told the Wall Street Journal in an interview published on...
By Pete Schroeder WASHINGTON (Reuters) - Emboldened by a friendlier incoming Trump administration and their success last year in weakening draft capital hikes, big U.S. banks plan...
-- India's foreign exchange reserves have been on a declining trend for six consecutive weeks, standing at a 10-month low of $625.87 billion as of Jan. 10, according...
-- The Dutch government has been excluding billions of euros in sales by tech company ASML (AS:ASML) to China from its disclosures on exports of sensitive goods,...
Investors may be overlooking the long-term growth opportunities of the healthcare sector. JPMorgan Asset Management global market strategist Stephanie Aliaga sits down with Seana Smith and Brad Smith on Morning Brief to discuss her bullish outlook for the health care sector (XLV). The strategist compares the healthcare sector's positioning to the financial sector's recent gains. "This week posted really strong reports, particularly in profitability. That's a part of the market on financials that is benefiting from a lot of the kind of macro tailwinds on deregulation, but also a soft landing," she says. "I think some similar things can be said for healthcare." "Healthcare is massively underperformed. I think a big theme for us this year when rebalancing portfolios is looking where expectations are relative to the kind of potential and earnings delivery expected," Aliaga says, adding that healthcare is an "industry that is ripe for innovation, ripe for M&A and partnerships this coming year." She notes that medtech and pharma are two particular areas in healthcare that are positioned to benefit "ahead of the upcoming patent cycle." With Trump returning to the White House, Aliaga notes that there is "a lot of uncertainty." The strategist adds, "I think there is absolutely bipartisan support for lowering the drug prices, but then you also have to balance that with the incentives that these companies have: to continue to push the bar forward when it comes to innovation." To watch more expert insights and analysis on the latest market action, check out more Morning Brief here. This post was written by Naomi Buchanan.
PROVIDENCE, R.I. - Citizens Financial Group, Inc. (NYSE:CFG) reported on Friday fourth quarter earnings that exceeded analyst expectations, driven by strong execution of key...
-- Volkswagen (ETR:VOWG_p) is exploring ways to strengthen its collaboration with US-based electric vehicle (EV) manufacturer Rivian (NASDAQ:RIVN), the German auto...
-- BMO Capital raised its target for Amazon (NASDAQ:AMZN) to $265 from $236 in a note Friday, citing a robust outlook for Amazon Web Services (AWS) and continued...
NEW YORK - Truist Financial Corp. (NYSE:TFC) reported fourth quarter earnings and revenue that surpassed analyst expectations, sending its shares up 1.76% in early trading. The...
(Reuters) - The U.S. auto safety regulator closed its probe into 6,971 Fisker (OTC:FSRNQ) Ocean SUVs on Friday over inadvertent activation of the automatic emergency braking...